GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool

How Long to Take + How to Stop GLP-1 Therapy (India, 2026)

STEP-4 trial evidence · Indian guideline context · Updated May 2026

The short answer

For obesity: typical duration is 12-24+ months of continuous therapy, often extended to 5-10 years for patients who tolerate it. For type 2 diabetes: long-term, similar to metformin. The biggest concern with stopping: STEP-4 trial showed ~two-thirds weight regain within 12 months of discontinuation. Semaglutide can be stopped safely without medical taper (no withdrawal symptoms), but weight regain is the norm. Take the 5-min eligibility check to see what fits your timeline.

First — see if GLP-1 fits at all

5-min Indian-guideline eligibility check.

Take the free assessment →

How long do you take GLP-1 therapy?

GLP-1 therapy duration depends on indication. For type 2 diabetes, GLP-1 is typically continued long-term as part of standard glycaemic management — there is no defined “course” in the antibiotic sense. For obesity / chronic weight management, the framework is different but the direction is similar: evidence supports indefinite long-term therapy with periodic reassessment.

Typical Indian endocrinology framing

  • · Months 0-4: Titration phase. Doses escalate weekly or bi-weekly to reach target maintenance dose (semaglutide 2.4 mg, tirzepatide 10-15 mg).
  • · Months 4-12: Active weight-loss phase. Most patients hit peak weight loss around month 9-12 (STEP-1 68-week protocol).
  • · Months 12-24: Maintenance phase. Continue therapy to consolidate the weight loss; muscle-preserving exercise becomes critical.
  • · Year 2+: Continued long-term, with periodic specialist review (every 6-12 months). Dose may be reduced if maintenance is stable.

The decision to stop is typically driven by cost (especially for innovator brands) or by reaching a personal weight target with confidence in sustained lifestyle changes. Stopping is not a clinical default after a fixed duration.

What happens if you stop — STEP-4 trial evidence

The STEP-4 trial (Rubino et al., JAMA 2021) is the strongest evidence on what happens after stopping semaglutide.

STEP-4 design

902 adults with obesity received semaglutide 2.4 mg weekly for 20 weeks. At week 20, those who had lost weight were randomised: half continued semaglutide, half switched to placebo. Both groups continued lifestyle counselling. Outcomes assessed at week 68.

STEP-4 results

  • · Continued semaglutide: lost an additional 7.9% body weight (total 17% loss from baseline)
  • · Switched to placebo: regained 6.9% body weight (net loss reduced to ~5% from baseline)
  • · Net difference: ~14% body weight

In plain terms: continuing the drug = continued benefit; stopping the drug = most of the benefit erodes over 12 months. This applies to semaglutide and tirzepatide both (class effect). Read the full STEP-4 trial summary →

How to stop GLP-1 therapy safely

GLP-1 receptor agonists do not cause withdrawal symptoms. There is no required medical taper. However, the practical approach matters:

  1. 1. Discuss with your specialist first. Plan the timing — typically after achieving target weight + 6-12 months of stable maintenance. Document baseline weight, BP, HbA1c before stopping for comparison.
  2. 2. Anchor lifestyle changes. The 2-4 weeks before stopping is when to maximise dietary and exercise discipline. Habits formed under therapy can hold up after stopping if they were genuinely embedded.
  3. 3. Manage concurrent medications. If you’re on insulin or sulfonylureas for T2D alongside GLP-1, these may need dose increases when GLP-1 stops (since glycaemic control reduces). Your endocrinologist will manage this.
  4. 4. Expect appetite return. Appetite signals return to pre-treatment levels within 2-4 weeks. Plan accordingly — meal structure, snack pre-emption, hydration.
  5. 5. Schedule follow-up. 3-month and 6-month check-ins to assess weight, blood markers, and decide whether to resume therapy.
  6. 6. Plan a re-treatment option. If significant regain occurs, restarting semaglutide typically restores the weight benefit. Many patients run intermittent therapy cycles for cost reasons.

If cost is the reason you want to stop

For many Indian patients, the trigger for considering stopping is cost — particularly on Ozempic (₹5,660-9,100/month) or Mounjaro (₹14,000-27,500/month). Before stopping, consider switching to an Indian generic instead:

Cost-mitigation paths

  • · Switch from Ozempic to Noveltreat (Sun Pharma, ₹750-2,000/month) — same molecule, 3-12× cheaper
  • · Switch from Wegovy to Poviztra (Emcure-distributed Novo Nordisk Wegovy, ₹3,999-8,999/month) — same molecule, Indian-distribution-friendly
  • · Use Sundae at ₹220/shot for the cheapest option (vial format)
  • · Pair with an independent endocrinologist consult (₹500-1,500 vs ₹2,500+ at hospital outpatient) for further cost reduction

See all Ozempic alternatives →

Frequently asked questions

How long should I take semaglutide / Ozempic / Wegovy?+
For obesity (chronic weight management), evidence supports indefinite long-term therapy with periodic reassessment — typical Indian endocrinology practice is 12-24+ months of continuous therapy, then a discussion of whether sustained lifestyle changes can support a taper. For type 2 diabetes, GLP-1 therapy is typically continued long-term as part of standard diabetes management, similar to metformin or insulin. The STEP-4 trial (NEJM 2021) showed that patients who stopped semaglutide regained approximately two-thirds of lost weight within 12 months, which is the strongest evidence for sustained therapy.
What happens if I stop semaglutide / Ozempic / Wegovy / Mounjaro?+
Most patients regain weight after stopping. STEP-4 trial (Rubino et al., JAMA 2021): all patients took semaglutide for 20 weeks (week-20 weight: -10.6% from baseline), then half continued and half switched to placebo. By week 68, the continuation group reached -17.4% from baseline; the placebo group regained ~6.9% during the 48-week post-switch period, ending at -5.0% from baseline. Net difference between continuation and stopping at trial end: ~12 percentage points. The biological reason: GLP-1 reduces appetite and improves satiety; removing the drug returns appetite signals to pre-treatment levels. Sustained lifestyle changes can mitigate but rarely eliminate the regain.
Is it safe to stop semaglutide suddenly?+
Yes — semaglutide can be stopped without a medical taper. Unlike some drugs (steroids, antidepressants), GLP-1 receptor agonists don't cause withdrawal symptoms when discontinued. However, sudden stopping is rarely the ideal clinical approach: appetite typically returns within 2-4 weeks, GI side effects that resolved on therapy may not be a problem, but the weight benefit erodes. Most endocrinologists recommend a structured discussion rather than an abrupt stop. For type 2 diabetes patients on insulin or sulfonylureas alongside GLP-1, dose adjustments to other diabetes medications may be needed when stopping.
Can I take semaglutide for life?+
In principle, yes — GLP-1 receptor agonists have a well-characterised long-term safety profile, with the largest published follow-up at ~5 years (SUSTAIN-6, SELECT, etc.). For type 2 diabetes, long-term use is standard. For obesity, the practical question is cost and tolerability rather than safety. Many Indian endocrinologists support 5-10 year therapy timelines for obesity-indication patients who tolerate it well, with periodic reviews of dose and continued benefit.
How do I stop semaglutide without regaining weight?+
Honest answer: substantial weight regain after stopping is the norm, not the exception. STEP-4 showed ~two-thirds regain. The mitigating strategies that have evidence: (1) sustain the dietary changes embedded during therapy; (2) maintain exercise (resistance training particularly helps preserve muscle mass); (3) consider transitioning to a lower-cost long-term option (Indian generic semaglutide at ₹220-3,500/month, much cheaper than innovator brands); (4) plan periodic re-treatment cycles if continuous therapy isn't financially viable. Some endocrinologists are now exploring "low-dose maintenance" protocols (0.5-1 mg semaglutide weekly) after target weight is achieved — early results are promising but not yet guideline-backed.
Will my type 2 diabetes come back if I stop Ozempic?+
Likely yes — semaglutide doesn't cure T2D, it manages it. When you stop, the underlying insulin resistance and beta-cell dysfunction return. HbA1c typically rises back toward pre-treatment levels within 8-16 weeks of stopping. Some patients who achieved sustained T2D remission via substantial weight loss + lifestyle intervention can maintain glycaemic control after stopping, but this is the exception. For most T2D patients, GLP-1 is intended as long-term therapy, similar to metformin.
Can I take a break from semaglutide / Ozempic?+
A planned therapy break (often called a “drug holiday”) is sometimes considered for patients who have hit their target weight and want to test life without the drug. Realistic expectations: most patients regain weight; some find that the sustained lifestyle changes made during therapy hold up; a return to therapy after weight regain typically restores the benefit. If you plan a break, discuss the timing with your endocrinologist — typically schedule the break after the achievement of stable target weight + 6-12 months of maintenance, and plan a follow-up at 3 and 6 months to assess regain.
I want to get pregnant. When should I stop semaglutide?+
GLP-1 receptor agonists are not recommended during pregnancy. The label-recommended approach: discontinue semaglutide at least 2 months before planned conception (this is the washout window in current guidelines). The biological rationale: GLP-1 receptor agonists have a long half-life (~1 week for semaglutide); 2 months ensures the drug has cleared. If you become pregnant while on semaglutide, stop immediately and discuss with your obstetrician. There is no evidence of major fetal harm from early-pregnancy exposure but the precautionary principle applies.

Related guides

STEP-4 trial — full summary →Weight regain after stopping GLP-1 →How to get GLP-1 in India (start) →Ozempic alternatives in India →India 2026 pricing →All India semaglutide brands →

Find your right starting point

5-min Indian-guideline eligibility check. Helps map your case to the right molecule, dose, and treatment plan.

Take the free assessment →

Discontinuation decisions should always be made in consultation with a registered medical practitioner. GLP-1 therapies (semaglutide, tirzepatide) are Schedule H drugs in India. STEP-4 trial reference: Rubino et al., JAMA 2021. GLP-1 Check is informational and not a substitute for clinical judgment.